एम्लोडिपिन और बेनाज़ेप्रिल के इंटरैक्शन

Calcium Channel Blockers Felodipine Nisoldipine Contraindicated during and 2 weeks after TOLSURA treatment. (इट्राकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (एप्टिफिबाटाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil. (एस्मोलोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (कैप्टोप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Calcium Channel Blockers: Avoid concomitant use with Calcium Chloride Injection. (कैल्शियम क्लोराइड लेबल, दवाओं के इंटरैक्शन)

…with colchicine; markedly increased transaminases with lomitapide; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia and cardiac arrhythmias (e.g., torsades de pointes) with disopyramide; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). (क्लैरिथ्रोमाइसिन लेबल, चेतावनियां और सावधानियां)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (क्लोज़ापिन लेबल, बॉक्स्ड चेतावनी)

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (टैडालाफिल लेबल, चेतावनियां और सावधानियां)

The concomitant use of RYANODEX and calcium channel blockers is not recommended during the treatment of malignant hyperthermia. (डैंट्रोलीन लेबल, दवाओं के इंटरैक्शन)

Perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor. (पेरिंडोप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

ये दवाएं पोटैशियम का उत्सर्जन कम करती हैं; इनके साथ पोटैशियम सप्लीमेंट या नमक के विकल्प (सॉल्ट सब्स्टीट्यूट) जोड़ने से हाइपरकेलेमिया हो सकता है, जो दिल की धड़कन की लय पर असर डालता है। (NIH Office of Dietary Supplements, Potassium)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (फेरिक साइट्रेट लेबल, दवाओं के इंटरैक्शन)

CONTRAINDICATIONS Fosinopril sodium tablets are contraindicated in patients who are hypersensitive to this product or to any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema with any other ACE inhibitor therapy). (फोसिनोप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Fosinopril sodium and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to fosinopril, to any other ACE inhibitor, to hydrochlorothiazide, or other sulfonamide-derived drugs, or any other ingredient or component in the formulation. (फोसिनोप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function. (बीटाक्सोलोल लेबल, दवाओं के इंटरैक्शन)

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (बेनाज़ेप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (मेटोलाज़ोन लेबल, चेतावनियां)

Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (रैमिप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

IV administration of non-dihydropyridine calcium-channel antagonists (e.g., verapamil) Hypersensitivity reactions, including anaphylaxis, to labetalol Bronchial asthma ( 4 ) (लेबेटालोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not administer amlodipine and benazepril hydrochloride capsules within 36 hours of switching to or from a neprilysin inhibitor, e.g., sacubitril/valsartan [see Warnings and Precautions (5.1) ]. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not administer amlodipine and benazepril hydrochloride capsules within 36 hours of switching to or from a neprilysin inhibitor, e.g., sacubitril/valsartan [see Warnings and Precautions (5.1) ]. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (अल्फुज़ोसिन लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Calcium Antagonists FORANE may lead to marked hypotension in patients treated with calcium antagonists. (आइसोफ्लुरेन लेबल, दवाओं के इंटरैक्शन)

Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. (आइसोसॉर्बाइड मोनोनाइट्रेट लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (इलोपेरिडोन लेबल, चेतावनियां और सावधानियां)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Do not exceed doses greater than 20 mg daily of simvastatin (7.1) mTOR inhibitors: increased risk of angioedema ( 7.1 ) (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

(See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (एटेनोलोल लेबल, चेतावनियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (एटोमोक्सेटिन लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (एपोप्रोस्टेनोल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

• Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher amlodipine and atorvastatin dosage. (एम्लोडिपिन और एटोरवास्टेटिन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (एल्टेप्लेज़ लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (एवानाफिल लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (एसेनापिन लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (ऑक्ट्रियोटाइड लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (ओलैंज़ापिन लेबल, चेतावनियां और सावधानियां)

…and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (ओलैंज़ापिन और फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (कार्बिडोपा लेबल, दवाओं के इंटरैक्शन)

Antihypertensive drugs: May cause symptomatic postural hypotension. (कार्बिडोपा और लेवोडोपा लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, दवाओं के इंटरैक्शन)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (कार्वेडिलोल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (कैरिप्राज़िन लेबल, चेतावनियां और सावधानियां)

Calcium Channel Blockers : Administration of calcium may reduce the response. (कैल्शियम ग्लूकोनेट लेबल, दवाओं के इंटरैक्शन)

Drugs that affect sinus node function or AV node conduction (e.g., digitalis, calcium channel blockers, beta blockers) Clinical Implication Concomitant use of drugs that affect sinus node function or AV node conduction with clonidine potentiate bradycardia and risk of AV block [see Warnings and Precautions (5.1) ]. (क्लोनिडिन लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

As with other ACE inhibitors, periodic monitoring of white blood cell counts in patients with collagen vascular disease and/or renal disease should be considered. (क्विनाप्रिल लेबल, चेतावनियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (क्वेटियापिन लेबल, चेतावनियां और सावधानियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema [see Drug Interactions (7)] . (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (टेराज़ोसिन लेबल, चेतावनियां और सावधानियां)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (टेस्टोस्टेरोन लेबल, चेतावनियां और सावधानियां)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (टैक्रोलिमस लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Monitor serum potassium during concomitant therapy with ( 7.2 ): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7.1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptan's AUC was 5.4 times as large and C max was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole [see Warnings… (टोल्वैप्टन लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Like other ACE inhibitors, trandolapril has only rarely been associated with symptomatic hypotension in uncomplicated hypertensive patients. (ट्रैंडोलाप्रिल लेबल, चेतावनियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (डाइएथिलप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (डिगॉक्सिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (डुलोक्सेटिन लेबल, चेतावनियां और सावधानियां)

• Antihypertensive Drugs: Monitor blood pressure. (डेक्समिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (डोफेटिलाइड लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (डोरज़ोलामाइड और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (ड्यूटास्टेराइड लेबल, दवाओं के इंटरैक्शन)

Calcium Channel Antagonists Dutasteride Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (ड्यूटास्टेराइड और टैम्सुलोसिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants. (ड्रोपेरिडोल लेबल, दवाओं के इंटरैक्शन)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (ड्रोस्पिरेनोन और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां और सावधानियां)

Antihypertensives: Possible additive hypotensive effects. (नाइट्रोग्लिसरीन लेबल, दवाओं के इंटरैक्शन)

ACE Inhibitors Benazepril: In healthy volunteers receiving single dose of 20 mg nifedipine ER and benazepril 10 mg, the plasma concentrations of benazeprilat and nifedipine in the presence and absence of each other were not statistically significantly different. (निफेडिपिन लेबल, दवाओं के इंटरैक्शन)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (निमोडिपिन लेबल, दवाओं के इंटरैक्शन)

Caution should also be used when niacin extended-release tablets are used in patients with unstable angina or in the acute phase of an MI, particularly when such patients are also receiving vasoactive drugs such as nitrates, calcium channel blockers, or adrenergic blocking agents. (नियासिन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Non-dihydropyridine Calcium Channel Blockers Because of significant negative inotropic and chronotropic effects in patients treated with β-blockers and calcium channel blockers of the verapamil and diltiazem type, monitor the ECG and blood pressure in patients treated concomitantly with these agents. (नेबिवोलोल लेबल, चेतावनियां और सावधानियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (पाज़ोपैनिब लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (पेंटोक्सिफाइलिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (पैलिपेरिडोन लेबल, चेतावनियां और सावधानियां)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (पैसिरियोटाइड लेबल, चेतावनियां और सावधानियां)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (पोटैशियम आयोडाइड लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (पोनेसिमोड लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (प्राज़ोसिन लेबल, चेतावनियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

In addition, patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE-inhibitors]) may be at increased risk of developing angioedema. (प्रीगैबलिन लेबल, चेतावनियां और सावधानियां)

The concomitant use of beta-adrenergic blockers and non-dihydropyridine calcium channel blockers (e.g., verapamil and diltiazem), digoxin or clonidine increases the risk of significant bradycardia. (प्रोप्रानोलोल लेबल, चेतावनियां और सावधानियां)

Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (फिनाइलएफ्रिन लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (फेनेलज़िन लेबल, चेतावनियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (बिसोप्रोलोल लेबल, चेतावनियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Amphetamines may decrease the hypotensive effect of antihypertensives. (बेंज़फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (बोर्टेज़ोमिब लेबल, चेतावनियां और सावधानियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (ब्रोमफेनिरामिन, स्यूडोएफेड्रिन और डेक्सट्रोमेथॉर्फन लेबल, दवाओं के इंटरैक्शन)

Use caution in patients taking antihypertensive medications. (ब्रोमोक्रिप्टिन लेबल, चेतावनियां और सावधानियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Drugs: Monitor blood pressure. (मिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (मिर्टाज़ापिन लेबल, चेतावनियां और सावधानियां)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (मेकामाइलामिन लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Examples: Drugs known to have potential to prolong QT interval: Class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers. (मेथाडोन लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Hypotension Moexipril hydrochloride can cause symptomatic hypotension, although, as with other ACE inhibitors, this is unusual in uncomplicated hypertensive patients treated with moexipril hydrochloride alone. (मोएक्सिप्रिल लेबल, चेतावनियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (रियोसिगुआट लेबल, चेतावनियां और सावधानियां)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Lithium: Increased serum lithium levels; toxicity symptoms ( 7.1 ) (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (लुमाटेपेरोन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Examples of relevant classes of compounds where antacids have been demonstrated to reduce bioavailability include antibiotics (such as quinolones, ampicillin, and tetracyclines), thyroid hormones, ACE inhibitors, statin lipid regulators, and anti-malarials. (लैंथेनम लेबल, दवाओं के इंटरैक्शन)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (लैकोसामाइड लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (लोमिटापाइड लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (ल्यूरासिडोन लेबल, चेतावनियां और सावधानियां)

…propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem,… (वारफेरिन लेबल, दवाओं के इंटरैक्शन)

Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (वार्डेनाफिल लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

In the literature, three cases of hyperkalemia in elderly patients have been reported after concomitant intake of sulfamethoxazole/trimethoprim and an angiotensin converting enzyme inhibitor. (सल्फामेथॉक्साज़ोल और ट्राइमेथोप्रिम लेबल, दवाओं के इंटरैक्शन)

Table 2: Drugs that Potentiate Cyclophosphamide Toxicities Toxicity Drugs Increased hematotoxicity and/or immunosuppression ● ACE inhibitors: ACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity… (साइक्लोफॉस्फामाइड लेबल, दवाओं के इंटरैक्शन)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (साइक्लोबेंज़ाप्रिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Do not exceed doses greater than 20 mg daily of simvastatin (7.1) mTOR inhibitors: increased risk of angioedema ( 7.1 ) (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema [see Drug Interactions (7)] . (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (सिलोडोसिन लेबल, चेतावनियां और सावधानियां)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (सिल्डेनाफिल लेबल, चेतावनियां और सावधानियां)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Initiate and/or adjust antihypertensive therapy as appropriate. (सुनिटिनिब लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inhibitors : Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (सेवोफ्लुरेन लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

When involvement of the tongue, glottis, or larynx appears likely to cause airway obstruction, appropriate therapy, e.g., administer subcutaneous epinephrine injection 1:1000 (0.3 to 0.5 mL), promptly [see Adverse Reactions (6)]. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (इकाटिबेंट लेबल, दवाओं के इंटरैक्शन)

In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (इसराडिपिन लेबल, दवाओं के इंटरैक्शन)

Use with Angiotensin-Converting Enzyme Inhibitors: The use of angiotensin-converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce anemia and severe leukopenia. (एज़ाथियोप्रिन लेबल, दवाओं के इंटरैक्शन)

Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (एडेनोसिन लेबल, दवाओं के इंटरैक्शन)

Neutropenia/Agranulocytosis Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment especially if they also have a collagen vascular disease. (एनालाप्रिलैट लेबल, चेतावनियां)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (एफेड्रिन लेबल, दवाओं के इंटरैक्शन)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (क्लोरप्रोमाज़िन लेबल, चेतावनियां)

Interactions with other dihydropyridine calcium channel blockers have not been reported, but these agents (including felodipine, nicardipine, and nimodipine ) are all dependent upon P450 IIIA4 for metabolism, so similar interactions with quinidine should be anticipated. (क्विनिडिन लेबल, दवाओं के इंटरैक्शन)

No other formal drug-drug interaction studies between zafirlukast and marketed drugs known to be metabolized by the P450 3A4 (CYP3A4) isoenzyme (e.g., dihydropyridine calcium-channel blockers, cyclosporin, cisapride) have been conducted. (ज़ाफिरलुकास्ट लेबल, सावधानियां)

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (टर्बिनाफिन लेबल, दवाओं के इंटरैक्शन)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (ट्राइफ्लुओपेराज़िन लेबल, सावधानियां)

Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

…malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants. [see Contraindications (4), Clinical Pharmacology (12.5)] Signs consistent with malignant hyperthermia may include hyperthermia, hypoxia,… (डेसफ्लुरेन लेबल, चेतावनियां और सावधानियां)

This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (डेसिप्रामिन लेबल, चेतावनियां)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (डेसोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां)

Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (नाइट्रोप्रुसाइड लेबल, चेतावनियां)

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (निसोल्डिपिन लेबल, दवाओं के इंटरैक्शन)

The antihypertensive action of guanethidine and similar agents may be blocked. (नॉरट्रिप्टिलीन लेबल, चेतावनियां)

Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, calcium channel blockers and cimetidine. (पिमेक्रोलिमस लेबल, दवाओं के इंटरैक्शन)

When involvement of the tongue, glottis, or larynx appears likely to cause airway obstruction, appropriate therapy, e.g., administer subcutaneous epinephrine injection 1:1000 (0.3 to 0.5 mL), promptly [see Adverse Reactions (6)]. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (प्रोक्लोरपेराज़िन लेबल, सावधानियां)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (प्रोट्रिप्टिलीन लेबल, चेतावनियां)

Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (फिंगोलिमोड लेबल, दवाओं के इंटरैक्शन)

…studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (फिनास्टेराइड लेबल, दवाओं के इंटरैक्शन)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (ब्यूटॉर्फेनॉल लेबल, चेतावनियां)

When involvement of the tongue, glottis, or larynx appears likely to cause airway obstruction, appropriate therapy, e.g., administer subcutaneous epinephrine injection 1:1000 (0.3 to 0.5 mL), promptly [see Adverse Reactions (6)]. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (मिथाइलडोपा लेबल, दवाओं के इंटरैक्शन)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (मेक्सिलेटिन लेबल, दवाओं के इंटरैक्शन)

Because of its relative beta 1 cardio-selectivity, however, Metoprolol Tartrate Tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (मेटोप्रोलोल लेबल, चेतावनियां और सावधानियां)

When involvement of the tongue, glottis, or larynx appears likely to cause airway obstruction, appropriate therapy, e.g., administer subcutaneous epinephrine injection 1:1000 (0.3 to 0.5 mL), promptly [see Adverse Reactions (6)]. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

QUELICIN can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants. [see Contraindications (4) , Clinical Pharmacology (12.5) ] . (सक्सिनिलकोलिन लेबल, चेतावनियां और सावधानियां)

Drug Interactions Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline,… (सिडोफोविर लेबल, दवाओं के इंटरैक्शन)

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (हाइड्रालाज़िन लेबल, दवाओं के इंटरैक्शन)

Calcium channel blocking agents: Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials. (इब्यूटिलाइड लेबल, दवाओं के इंटरैक्शन)